Using Aduhelm Trick, Biogen Seeks Approval For Another Alzheimer’s Drug
The new drug from Biogen and partner Eisai, lecanemab, will attempt to use the same process that led to the recent approval of controversial drug Aduhelm. Meanwhile, Massachusetts' biggest health care provider, Mass General Brigham, has said it will not offer Aduhelm to patients.